-
1
-
-
29944436855
-
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
-
Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
-
(2006)
JAMA
, vol.295
, pp. 65-73
-
-
Chen, C.J.1
Yang, H.I.2
Su, J.3
Jen, C.L.4
You, S.L.5
Lu, S.N.6
-
2
-
-
33644858331
-
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
-
Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
-
(2006)
Gastroenterology
, vol.130
, pp. 678-686
-
-
Iloeje, U.H.1
Yang, H.I.2
Su, J.3
Jen, C.L.4
You, S.L.5
Chen, C.J.6
-
3
-
-
0029893146
-
Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B
-
Niederau C., Heintges T., Lenge S., Goldmann G., Niederau C.M., Mohr L., et al. Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
-
(1996)
N Engl J Med
, vol.334
, pp. 1422-1427
-
-
Niederau, C.1
Heintges, T.2
Lenge, S.3
Goldmann, G.4
Niederau, C.M.5
Mohr, L.6
-
4
-
-
19544391413
-
Lamivudine for patients with chronic hepatitis B and advanced liver disease
-
Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
-
(2004)
N Engl J Med
, vol.351
, pp. 1521-1531
-
-
Liaw, Y.F.1
Sung, J.J.2
Chow, W.C.3
Farrell, G.4
Lee, C.Z.5
Yuen, H.6
-
5
-
-
4644295202
-
Clinical outcome of HBeAg-negative chronic hepatitis in relation to virological response to lamivudine
-
Di Marco V., Marzano A., Lampertico P., Andreone P., Santantonio T., Almasio P.L., et al. Clinical outcome of HBeAg-negative chronic hepatitis in relation to virological response to lamivudine. Ann Int Med 40 (2004) 883-891
-
(2004)
Ann Int Med
, vol.40
, pp. 883-891
-
-
Di Marco, V.1
Marzano, A.2
Lampertico, P.3
Andreone, P.4
Santantonio, T.5
Almasio, P.L.6
-
6
-
-
35748984106
-
The clinical significance of persistently normal ALT in chronic hepatitis B infection
-
Lai M., Hyatt B.J., Nasser I., Curry M., and Afdhal N.H. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 47 (2007) 760-767
-
(2007)
J Hepatol
, vol.47
, pp. 760-767
-
-
Lai, M.1
Hyatt, B.J.2
Nasser, I.3
Curry, M.4
Afdhal, N.H.5
-
7
-
-
0036999977
-
Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminases
-
Yang L.M., Xu K.C., Zhao Y.L., Wu Z.R., Chen T.F., Qin Z.Y., et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminases. Chin J Dig Dis 4 (2002) 150-153
-
(2002)
Chin J Dig Dis
, vol.4
, pp. 150-153
-
-
Yang, L.M.1
Xu, K.C.2
Zhao, Y.L.3
Wu, Z.R.4
Chen, T.F.5
Qin, Z.Y.6
-
8
-
-
27444441182
-
Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications
-
Yuen M.F., Yuan H.J., Wong D.K.H., Yuen J.C., Wong W.M., Chan A.O., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
-
(2005)
Gut
, vol.54
, pp. 1610-1614
-
-
Yuen, M.F.1
Yuan, H.J.2
Wong, D.K.H.3
Yuen, J.C.4
Wong, W.M.5
Chan, A.O.6
-
9
-
-
33847701354
-
Chronic hepatitis B
-
Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
-
(2007)
Hepatology
, vol.45
, pp. 507-539
-
-
Lok, A.S.1
McMahon, B.J.2
-
10
-
-
40949135428
-
-
EASL International Consensus Conference on Hepatitis B. J Hepatol 2003;38:S3-S25.
-
EASL International Consensus Conference on Hepatitis B. J Hepatol 2003;38:S3-S25.
-
-
-
-
11
-
-
20444363583
-
Asian-pacific consensus statement on the management of chronic hepatitis B: a 2005 update
-
Liaw Y.F., Leung N., Guan R., Lau G.K., Merican I., McCaughan G., et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25 (2005) 472-489
-
(2005)
Liver Int
, vol.25
, pp. 472-489
-
-
Liaw, Y.F.1
Leung, N.2
Guan, R.3
Lau, G.K.4
Merican, I.5
McCaughan, G.6
-
12
-
-
33746339209
-
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update
-
Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 936-962
-
-
Keeffe, E.B.1
Dieterich, D.T.2
Han, S.H.3
Jacobson, I.M.4
Martin, P.5
Schiff, E.R.6
-
13
-
-
40949124903
-
-
Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD, Kotzev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. American Association for the Study of Liver Diseases, 58th annual meeting, 2007: late breaking abstract 2. Hepatology 2007;46:290A.
-
Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD, Kotzev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. American Association for the Study of Liver Diseases, 58th annual meeting, 2007: late breaking abstract 2. Hepatology 2007;46:290A.
-
-
-
-
14
-
-
40949126690
-
-
Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103. American Association for the Study of Liver Diseases, 58th annual meeting, 2007: late breaking abstract 6. Hepatology 2007;46:861A.
-
Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103. American Association for the Study of Liver Diseases, 58th annual meeting, 2007: late breaking abstract 6. Hepatology 2007;46:861A.
-
-
-
-
15
-
-
36348953975
-
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off therapy viral suppression
-
Yoo B.C., Kim J.H., Kim T.H., Koh K.C., Um S.H., Kim Y.S., et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off therapy viral suppression. Hepatology 46 (2007) 1041-1048
-
(2007)
Hepatology
, vol.46
, pp. 1041-1048
-
-
Yoo, B.C.1
Kim, J.H.2
Kim, T.H.3
Koh, K.C.4
Um, S.H.5
Kim, Y.S.6
-
16
-
-
40949149632
-
-
Gish R, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg-positive chronic hepatitis B infection: observations from antiviral-naïve patients treated with entecavir or lamivudine. 57th annual meeting of the American Association for the Study of Liver Diseases, 2006. Hepatology 2006;44:558A.
-
Gish R, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg-positive chronic hepatitis B infection: observations from antiviral-naïve patients treated with entecavir or lamivudine. 57th annual meeting of the American Association for the Study of Liver Diseases, 2006. Hepatology 2006;44:558A.
-
-
-
-
17
-
-
33845671388
-
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
-
Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
-
(2006)
Gastroenterology
, vol.131
, pp. 1743-1751
-
-
Hadziyannis, S.J.1
Tassopoulos, N.C.2
Heathcote, E.J.3
Chang, T.T.4
Kitis, G.5
Rizzetto, M.6
-
18
-
-
40949142486
-
Four-year entecavir treatment in nucleoside-naive HbeAg+ patients: results from studies ETV-022 and -901
-
Han S., Chang T.T., Chao Y.C., Yoon S.-K., Gish R.G., Cheinquer H., et al. Four-year entecavir treatment in nucleoside-naive HbeAg+ patients: results from studies ETV-022 and -901. Hepatology 46 (2007) 654A
-
(2007)
Hepatology
, vol.46
-
-
Han, S.1
Chang, T.T.2
Chao, Y.C.3
Yoon, S.-K.4
Gish, R.G.5
Cheinquer, H.6
-
19
-
-
40949103676
-
Long-term follow-up of entecavir treated protocol-defined nonresponders in rollover study ETV-901
-
Sherman M., Rizzetto M., Lai C.L., Liaw Y.-F., Gadano A., Jacobson I.M., et al. Long-term follow-up of entecavir treated protocol-defined nonresponders in rollover study ETV-901. Hepatology 46 (2007) 682A
-
(2007)
Hepatology
, vol.46
-
-
Sherman, M.1
Rizzetto, M.2
Lai, C.L.3
Liaw, Y.-F.4
Gadano, A.5
Jacobson, I.M.6
-
20
-
-
34548758435
-
Telaprevir and pegylated interferon-alpha-2a inhibit wild type and resistant genotype 1 hepatitis C virus replication in patients
-
Kieffer T.L., Sarrazin C., Miller J.S., Welker M.W., Forestier N., Reesink H.W., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46 (2007) 631-639
-
(2007)
Hepatology
, vol.46
, pp. 631-639
-
-
Kieffer, T.L.1
Sarrazin, C.2
Miller, J.S.3
Welker, M.W.4
Forestier, N.5
Reesink, H.W.6
-
21
-
-
23244453590
-
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B
-
Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
-
(2005)
Gastroenterology
, vol.129
, pp. 528-536
-
-
Lai, C.L.1
Leung, N.2
Teo, E.K.3
Tong, M.4
Wong, F.5
Hann, H.W.6
-
22
-
-
35648982926
-
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients
-
Lampertico P., Viganò M., Manenti E., Iavarone M., Sablon E., and Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
-
(2007)
Gastroenterology
, vol.133
, pp. 1445-1451
-
-
Lampertico, P.1
Viganò, M.2
Manenti, E.3
Iavarone, M.4
Sablon, E.5
Colombo, M.6
-
23
-
-
40849091053
-
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B
-
Sung J.J.Y., Lai J.Y., Zeuzem S., Chow W.C., Heathcote E.J., Perrillo R.P., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48 (2008) 728-735
-
(2008)
J Hepatol
, vol.48
, pp. 728-735
-
-
Sung, J.J.Y.1
Lai, J.Y.2
Zeuzem, S.3
Chow, W.C.4
Heathcote, E.J.5
Perrillo, R.P.6
-
24
-
-
40849132370
-
96 weeks combination of adefovir dipivoxil plus emtricitabine versus adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B
-
Hui C.K., Zhang H.Y., Bowden S., Locarnini S., Luk J.M., Leung K.-W., et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine versus adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 48 (2008) 714-720
-
(2008)
J Hepatol
, vol.48
, pp. 714-720
-
-
Hui, C.K.1
Zhang, H.Y.2
Bowden, S.3
Locarnini, S.4
Luk, J.M.5
Leung, K.-W.6
-
25
-
-
0142034717
-
A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine and adefovir for treatment-naive patients with chronic hepatitis B (CHB): week 52 analysis
-
Sung J.J.Y., Lau J.Y., Zeuzem S., Chow W.C., Heathcote E., Perrillo R., et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine and adefovir for treatment-naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 38 (2003) 25-26
-
(2003)
J Hepatol
, vol.38
, pp. 25-26
-
-
Sung, J.J.Y.1
Lau, J.Y.2
Zeuzem, S.3
Chow, W.C.4
Heathcote, E.5
Perrillo, R.6
-
26
-
-
30344457555
-
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
-
Lim S.G., Ng T.M., Kung N., Krastev Z., Volfova M., Husa P., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 166 (2006) 49-56
-
(2006)
Arch Intern Med
, vol.166
, pp. 49-56
-
-
Lim, S.G.1
Ng, T.M.2
Kung, N.3
Krastev, Z.4
Volfova, M.5
Husa, P.6
-
27
-
-
40949151291
-
First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection
-
Van Bommel F., De Man R.A., Erhardt A., Huppe D., Stein K., Buggish P., et al. First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection. Hepatology 46 (2007) 270A
-
(2007)
Hepatology
, vol.46
-
-
Van Bommel, F.1
De Man, R.A.2
Erhardt, A.3
Huppe, D.4
Stein, K.5
Buggish, P.6
-
28
-
-
33645215806
-
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients
-
Benhamou Y., Fleury H., Trimoulet P., Pellegrin I., Urbinelli R., Katlama C., et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 (2006) 548-555
-
(2006)
Hepatology
, vol.43
, pp. 548-555
-
-
Benhamou, Y.1
Fleury, H.2
Trimoulet, P.3
Pellegrin, I.4
Urbinelli, R.5
Katlama, C.6
-
29
-
-
40949087837
-
Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE Study)
-
Zeuzem S., Buti M., Gane E.J., Liaw Y.-F., Di Bisceglie A.M., Heathcote E.J., et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE Study). Hepatology 46 (2007) 681A
-
(2007)
Hepatology
, vol.46
-
-
Zeuzem, S.1
Buti, M.2
Gane, E.J.3
Liaw, Y.-F.4
Di Bisceglie, A.M.5
Heathcote, E.J.6
-
30
-
-
4544239807
-
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
-
Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
-
(2004)
N Engl J Med
, vol.351
, pp. 1206-1217
-
-
Marcellin, P.1
Lau, G.K.2
Bonino, F.3
Farci, P.4
Hadziyannis, S.5
Jin, R.6
-
31
-
-
21244447705
-
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
-
Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
-
(2005)
N Engl J Med
, vol.352
, pp. 2682-2695
-
-
Lau, G.K.1
Piratvisuth, T.2
Luo, K.X.3
Marcellin, P.4
Thongsawat, S.5
Cooksley, G.6
-
32
-
-
40949124478
-
-
http://clinicaltrials.gov/.
-
http://clinicaltrials.gov/.
-
-
-
-
33
-
-
34547148385
-
Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B
-
Keeffe E.B., Zeuzem S., Koff R.S., Dieterich D.T., Esteban-Mur R., Gane E.J., et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5 (2007) 890-897
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 890-897
-
-
Keeffe, E.B.1
Zeuzem, S.2
Koff, R.S.3
Dieterich, D.T.4
Esteban-Mur, R.5
Gane, E.J.6
|